12 Feb 2021 TUMAGNOSTIC – Phase 1 clinical trial
Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, has obtained very promising pre-clinical results with CP-506 drug, a new and improved Hypoxia Activated Prodrug. The company is finalising its Clinical Trial Application to obtain regulatory approval for the launch of its tumor agnostic Phase I Clinical Trial in 2021.
This will be a first in human dose escalation study to determine the safety, pharmacokinetics, pharmacodynamics and phase 2 recommended dose. At the same time, we will check for the first indication of antitumor effect in humans.
CP-506 will be tested in both monotherapy, with patient selection based on validated biomarkers, as well as in combination with standard treatments such as immune checkpoint inhibitors.